Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00091559
Status:
COMPLETED
Last Update Posted:
2017-04-05
First Post:
2004-09-10
Brief Title:
Oral SAHA Suberoylanilide Hydroxamic Acid in Advanced Cutaneous T-cell Lymphoma 0683-001
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid SAHA in Advanced Cutaneous T-cell Lymphoma
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study for patients diagnosed with advanced cutaneous T-cell lymphoma stage 1B or higher who have progressive persistent or recurrent disease on or following 2 other therapies one of which must have contained Targretin bexaroteneor for patients who are not candidates or could not tolerate Targretin therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004_015 | None | None | None |